| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Stem Neoplasms | 16 | 2020 | 191 | 3.970 |
Why?
|
| Brain Neoplasms | 44 | 2024 | 8856 | 2.770 |
Why?
|
| Glioma | 26 | 2024 | 3390 | 2.420 |
Why?
|
| Magnetic Resonance Imaging | 75 | 2024 | 35797 | 1.420 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2017 | 1995 | 1.180 |
Why?
|
| Neurofibromatosis 1 | 7 | 2022 | 555 | 1.020 |
Why?
|
| Diagnostic Imaging | 11 | 2023 | 3494 | 0.960 |
Why?
|
| Positron-Emission Tomography | 9 | 2018 | 6419 | 0.940 |
Why?
|
| Medulloblastoma | 9 | 2022 | 675 | 0.860 |
Why?
|
| Central Nervous System Neoplasms | 9 | 2022 | 890 | 0.840 |
Why?
|
| Child | 106 | 2024 | 78492 | 0.830 |
Why?
|
| Phantoms, Imaging | 5 | 2018 | 2469 | 0.770 |
Why?
|
| Infratentorial Neoplasms | 4 | 2021 | 96 | 0.660 |
Why?
|
| Child, Preschool | 72 | 2024 | 41390 | 0.630 |
Why?
|
| Magnetic Resonance Spectroscopy | 11 | 2019 | 3743 | 0.620 |
Why?
|
| Cerebellar Neoplasms | 6 | 2022 | 584 | 0.610 |
Why?
|
| Image Interpretation, Computer-Assisted | 6 | 2024 | 3306 | 0.600 |
Why?
|
| Cerebral Ventricles | 8 | 2012 | 540 | 0.590 |
Why?
|
| Nuclear Medicine | 1 | 2018 | 233 | 0.510 |
Why?
|
| Neuroradiography | 1 | 2015 | 71 | 0.510 |
Why?
|
| Brain Stem | 3 | 2019 | 853 | 0.470 |
Why?
|
| Ependymoma | 4 | 2022 | 319 | 0.470 |
Why?
|
| Astrocytoma | 4 | 2008 | 776 | 0.430 |
Why?
|
| Central Nervous System Diseases | 2 | 2015 | 517 | 0.430 |
Why?
|
| Neurology | 3 | 2018 | 767 | 0.430 |
Why?
|
| Radiopharmaceuticals | 2 | 2014 | 2655 | 0.420 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 5 | 2022 | 2767 | 0.410 |
Why?
|
| Adolescent | 69 | 2024 | 86278 | 0.410 |
Why?
|
| Infant | 45 | 2024 | 35456 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2019 | 20143 | 0.400 |
Why?
|
| Surface Plasmon Resonance | 2 | 2022 | 266 | 0.400 |
Why?
|
| Headache | 1 | 2019 | 1223 | 0.380 |
Why?
|
| Neurofibroma, Plexiform | 3 | 2013 | 66 | 0.380 |
Why?
|
| Brain | 21 | 2022 | 26597 | 0.370 |
Why?
|
| Research Report | 1 | 2013 | 359 | 0.350 |
Why?
|
| Benzimidazoles | 4 | 2022 | 858 | 0.320 |
Why?
|
| Humans | 142 | 2024 | 746630 | 0.320 |
Why?
|
| Societies, Medical | 2 | 2018 | 3790 | 0.310 |
Why?
|
| Meningeal Neoplasms | 5 | 2018 | 1227 | 0.310 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2023 | 8902 | 0.290 |
Why?
|
| Organizations | 1 | 2008 | 168 | 0.290 |
Why?
|
| Clinical Trials as Topic | 3 | 2018 | 7945 | 0.280 |
Why?
|
| Spinal Cord Diseases | 1 | 2009 | 288 | 0.280 |
Why?
|
| Quinolones | 4 | 2011 | 375 | 0.280 |
Why?
|
| Pediatrics | 3 | 2015 | 3562 | 0.280 |
Why?
|
| Neuroectodermal Tumors | 1 | 2006 | 22 | 0.270 |
Why?
|
| Male | 84 | 2024 | 351420 | 0.270 |
Why?
|
| Radiation Injuries | 3 | 2019 | 1175 | 0.270 |
Why?
|
| Spinal Cord Neoplasms | 3 | 2022 | 265 | 0.260 |
Why?
|
| Multicenter Studies as Topic | 2 | 2010 | 1679 | 0.260 |
Why?
|
| Female | 88 | 2024 | 382450 | 0.260 |
Why?
|
| Back Pain | 1 | 2009 | 540 | 0.260 |
Why?
|
| Hypothalamic Neoplasms | 3 | 2005 | 21 | 0.260 |
Why?
|
| Quinazolines | 4 | 2015 | 1355 | 0.260 |
Why?
|
| Retrospective Studies | 30 | 2024 | 78313 | 0.250 |
Why?
|
| Spinal Diseases | 2 | 2009 | 554 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2021 | 11584 | 0.250 |
Why?
|
| Contrast Media | 2 | 2016 | 5254 | 0.250 |
Why?
|
| Image Enhancement | 1 | 2015 | 2871 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2005 | 341 | 0.240 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2006 | 1419 | 0.240 |
Why?
|
| Neurofibromin 2 | 1 | 2005 | 268 | 0.230 |
Why?
|
| Temporal Muscle | 1 | 2023 | 36 | 0.230 |
Why?
|
| Permeability | 2 | 2018 | 725 | 0.230 |
Why?
|
| Antineoplastic Agents | 12 | 2021 | 13586 | 0.230 |
Why?
|
| Growth Charts | 1 | 2023 | 61 | 0.220 |
Why?
|
| Disease-Free Survival | 7 | 2017 | 6789 | 0.220 |
Why?
|
| Diencephalon | 2 | 2005 | 54 | 0.220 |
Why?
|
| Loss of Heterozygosity | 1 | 2005 | 665 | 0.210 |
Why?
|
| Scoliosis | 4 | 2003 | 716 | 0.210 |
Why?
|
| Diffusion | 2 | 2017 | 808 | 0.210 |
Why?
|
| Heredodegenerative Disorders, Nervous System | 1 | 2002 | 16 | 0.210 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2002 | 1064 | 0.210 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2013 | 4011 | 0.200 |
Why?
|
| Developmental Disabilities | 2 | 2010 | 1494 | 0.200 |
Why?
|
| Failure to Thrive | 2 | 2005 | 141 | 0.200 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2002 | 42 | 0.200 |
Why?
|
| Optic Nerve Glioma | 1 | 2021 | 32 | 0.200 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2023 | 122 | 0.190 |
Why?
|
| Histones | 2 | 2023 | 2552 | 0.190 |
Why?
|
| Nervous System Diseases | 2 | 2023 | 1612 | 0.190 |
Why?
|
| Meningioma | 2 | 2009 | 1203 | 0.180 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 275 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2016 | 9193 | 0.180 |
Why?
|
| Disease Progression | 8 | 2023 | 13317 | 0.180 |
Why?
|
| Contractile Proteins | 1 | 2000 | 242 | 0.170 |
Why?
|
| Infant, Newborn | 18 | 2015 | 25759 | 0.170 |
Why?
|
| Prenatal Diagnosis | 4 | 2011 | 1256 | 0.170 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2023 | 613 | 0.170 |
Why?
|
| Molecular Biology | 1 | 2023 | 579 | 0.170 |
Why?
|
| Cranial Nerve Neoplasms | 2 | 1997 | 134 | 0.170 |
Why?
|
| Combined Modality Therapy | 9 | 2021 | 8521 | 0.170 |
Why?
|
| Ultrasonography, Prenatal | 6 | 2012 | 1725 | 0.160 |
Why?
|
| Choristoma | 1 | 2000 | 210 | 0.160 |
Why?
|
| Tectum Mesencephali | 1 | 1998 | 19 | 0.160 |
Why?
|
| Perfusion Imaging | 1 | 2020 | 191 | 0.160 |
Why?
|
| Guanine | 2 | 2011 | 275 | 0.160 |
Why?
|
| Photons | 2 | 2019 | 584 | 0.160 |
Why?
|
| Hydrocephalus | 4 | 2011 | 752 | 0.150 |
Why?
|
| Prognosis | 10 | 2021 | 29079 | 0.150 |
Why?
|
| Craniopharyngioma | 1 | 2020 | 277 | 0.150 |
Why?
|
| Brain Diseases | 1 | 2007 | 1540 | 0.150 |
Why?
|
| Craniocerebral Trauma | 1 | 2002 | 486 | 0.150 |
Why?
|
| Neurosecretory Systems | 1 | 1999 | 222 | 0.150 |
Why?
|
| Optic Chiasm | 1 | 1997 | 91 | 0.150 |
Why?
|
| Endpoint Determination | 1 | 2020 | 588 | 0.150 |
Why?
|
| Radiation Oncology | 1 | 2023 | 554 | 0.140 |
Why?
|
| Dacarbazine | 2 | 2011 | 562 | 0.140 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 1174 | 0.140 |
Why?
|
| Endocrine System Diseases | 1 | 1999 | 247 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2013 | 2033 | 0.140 |
Why?
|
| Interferon-alpha | 1 | 2020 | 902 | 0.140 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 2029 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2000 | 1132 | 0.130 |
Why?
|
| Phenylketonurias | 1 | 1996 | 119 | 0.130 |
Why?
|
| Pituitary Neoplasms | 3 | 2020 | 1307 | 0.120 |
Why?
|
| Pons | 2 | 2019 | 239 | 0.120 |
Why?
|
| Piperazines | 2 | 2021 | 2472 | 0.120 |
Why?
|
| Indoles | 2 | 2016 | 1806 | 0.120 |
Why?
|
| Radiography | 8 | 2023 | 6950 | 0.120 |
Why?
|
| Anus, Imperforate | 1 | 1994 | 64 | 0.120 |
Why?
|
| Niacinamide | 1 | 2016 | 414 | 0.120 |
Why?
|
| Fetal Diseases | 2 | 2011 | 910 | 0.120 |
Why?
|
| Ice | 1 | 2014 | 102 | 0.110 |
Why?
|
| Orbital Diseases | 1 | 1996 | 183 | 0.110 |
Why?
|
| Radiotherapy Dosage | 4 | 2019 | 2894 | 0.110 |
Why?
|
| Orbital Neoplasms | 1 | 1996 | 225 | 0.110 |
Why?
|
| Neoplasms, Nerve Tissue | 1 | 2013 | 21 | 0.110 |
Why?
|
| Benchmarking | 1 | 2020 | 1028 | 0.110 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2011 | 326 | 0.110 |
Why?
|
| Hypoxia, Brain | 1 | 2014 | 137 | 0.110 |
Why?
|
| Camptothecin | 2 | 2013 | 591 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 5613 | 0.110 |
Why?
|
| Gene Deletion | 2 | 2006 | 2665 | 0.110 |
Why?
|
| Neural Tube Defects | 1 | 1994 | 252 | 0.100 |
Why?
|
| Treatment Outcome | 17 | 2021 | 63732 | 0.100 |
Why?
|
| Cranial Irradiation | 1 | 1995 | 392 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 6 | 2011 | 901 | 0.100 |
Why?
|
| Radionuclide Imaging | 3 | 2013 | 1979 | 0.100 |
Why?
|
| Microcephaly | 1 | 1996 | 428 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2020 | 10138 | 0.100 |
Why?
|
| ROC Curve | 3 | 2018 | 3497 | 0.100 |
Why?
|
| Survival Rate | 6 | 2013 | 12645 | 0.100 |
Why?
|
| Urogenital Abnormalities | 1 | 1994 | 256 | 0.100 |
Why?
|
| Visual Pathways | 1 | 1996 | 541 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 4122 | 0.100 |
Why?
|
| Telomerase | 1 | 2016 | 720 | 0.100 |
Why?
|
| Young Adult | 14 | 2024 | 57163 | 0.090 |
Why?
|
| Septum Pellucidum | 1 | 2011 | 53 | 0.090 |
Why?
|
| Neurofibromatoses | 2 | 2013 | 299 | 0.090 |
Why?
|
| Adult | 33 | 2022 | 215192 | 0.090 |
Why?
|
| Observer Variation | 7 | 2010 | 2574 | 0.090 |
Why?
|
| Neurofibromatosis 2 | 1 | 2004 | 385 | 0.090 |
Why?
|
| Thallium Radioisotopes | 2 | 2002 | 138 | 0.090 |
Why?
|
| Aspartic Acid | 2 | 2004 | 575 | 0.090 |
Why?
|
| Reproducibility of Results | 5 | 2014 | 19819 | 0.090 |
Why?
|
| Neuroma, Acoustic | 1 | 2013 | 449 | 0.090 |
Why?
|
| Antisickling Agents | 1 | 2010 | 76 | 0.090 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2010 | 81 | 0.090 |
Why?
|
| Meningitis | 2 | 2006 | 215 | 0.090 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2023 | 291 | 0.080 |
Why?
|
| Pregnancy Outcome | 4 | 2012 | 2853 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 6460 | 0.080 |
Why?
|
| Radiology | 1 | 2023 | 2084 | 0.080 |
Why?
|
| Angiomatosis | 1 | 2009 | 46 | 0.080 |
Why?
|
| Pyridines | 1 | 2021 | 2844 | 0.080 |
Why?
|
| Mutation | 3 | 2023 | 29627 | 0.080 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2006 | 138 | 0.080 |
Why?
|
| Hydroxyurea | 1 | 2010 | 284 | 0.080 |
Why?
|
| Vision Disorders | 1 | 1996 | 1065 | 0.080 |
Why?
|
| Follow-Up Studies | 12 | 2017 | 38771 | 0.080 |
Why?
|
| Water | 1 | 2014 | 1396 | 0.080 |
Why?
|
| Snake Venoms | 1 | 2008 | 40 | 0.080 |
Why?
|
| Medulla Oblongata | 1 | 1999 | 245 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 627 | 0.080 |
Why?
|
| Corpus Callosum | 2 | 2006 | 729 | 0.070 |
Why?
|
| Algorithms | 4 | 2020 | 13810 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 2830 | 0.070 |
Why?
|
| Monitoring, Intraoperative | 1 | 2014 | 931 | 0.070 |
Why?
|
| Prospective Studies | 10 | 2022 | 53253 | 0.070 |
Why?
|
| Hemorrhage | 2 | 2013 | 3521 | 0.070 |
Why?
|
| Anisotropy | 1 | 2010 | 1272 | 0.070 |
Why?
|
| Minority Groups | 1 | 2014 | 1197 | 0.070 |
Why?
|
| Palate, Soft | 1 | 2006 | 100 | 0.070 |
Why?
|
| Radiotherapy | 2 | 2010 | 1505 | 0.070 |
Why?
|
| Perioperative Care | 1 | 2014 | 999 | 0.070 |
Why?
|
| Forecasting | 1 | 2015 | 2907 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 12840 | 0.070 |
Why?
|
| Hydrazines | 1 | 2008 | 226 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2002 | 3985 | 0.070 |
Why?
|
| Adenoma | 1 | 1996 | 2139 | 0.070 |
Why?
|
| Emaciation | 1 | 2005 | 5 | 0.070 |
Why?
|
| United States | 8 | 2023 | 70437 | 0.060 |
Why?
|
| Mothers | 1 | 1996 | 2160 | 0.060 |
Why?
|
| Brain Damage, Chronic | 2 | 1997 | 267 | 0.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 661 | 0.060 |
Why?
|
| Supratentorial Neoplasms | 1 | 2006 | 158 | 0.060 |
Why?
|
| Busulfan | 1 | 2006 | 250 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 14543 | 0.060 |
Why?
|
| Central Nervous System | 2 | 2022 | 1330 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2022 | 1882 | 0.060 |
Why?
|
| Organoplatinum Compounds | 1 | 2006 | 402 | 0.060 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2010 | 953 | 0.060 |
Why?
|
| Collateral Circulation | 2 | 1997 | 276 | 0.060 |
Why?
|
| Necrosis | 2 | 2019 | 1596 | 0.060 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 15010 | 0.060 |
Why?
|
| Rhabdoid Tumor | 1 | 2006 | 205 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2016 | 3552 | 0.060 |
Why?
|
| Chromosomes, Human, X | 1 | 2006 | 302 | 0.060 |
Why?
|
| Neoplasms | 2 | 2023 | 21715 | 0.060 |
Why?
|
| Craniofacial Abnormalities | 1 | 2006 | 312 | 0.060 |
Why?
|
| Smith-Lemli-Opitz Syndrome | 1 | 2003 | 46 | 0.060 |
Why?
|
| Brain Abscess | 2 | 1995 | 117 | 0.060 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1996 | 2440 | 0.060 |
Why?
|
| Teratoma | 1 | 2006 | 397 | 0.060 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2006 | 281 | 0.060 |
Why?
|
| Cerebral Hemorrhage | 1 | 1995 | 2617 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2007 | 773 | 0.060 |
Why?
|
| Utah | 1 | 2023 | 129 | 0.050 |
Why?
|
| Endarterectomy | 1 | 1993 | 195 | 0.050 |
Why?
|
| Analysis of Variance | 4 | 2011 | 6226 | 0.050 |
Why?
|
| Cerebral Hemorrhage, Traumatic | 1 | 2002 | 20 | 0.050 |
Why?
|
| Pyrroles | 1 | 2009 | 1131 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2006 | 621 | 0.050 |
Why?
|
| Asphyxia Neonatorum | 1 | 2002 | 109 | 0.050 |
Why?
|
| Quality of Life | 1 | 2023 | 12977 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2011 | 12280 | 0.050 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 1033 | 0.050 |
Why?
|
| Leukodystrophy, Globoid Cell | 1 | 2001 | 32 | 0.050 |
Why?
|
| Gestational Age | 4 | 2011 | 3520 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2002 | 191 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 8305 | 0.050 |
Why?
|
| Thalidomide | 1 | 2006 | 882 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2005 | 589 | 0.050 |
Why?
|
| Cerebral Cortex | 3 | 2007 | 5717 | 0.050 |
Why?
|
| Skull Fractures | 1 | 2002 | 199 | 0.050 |
Why?
|
| Osteoblastoma | 1 | 2000 | 22 | 0.050 |
Why?
|
| Akinetic Mutism | 1 | 2000 | 11 | 0.050 |
Why?
|
| Birth Injuries | 1 | 2002 | 150 | 0.050 |
Why?
|
| Stroke | 1 | 2023 | 9693 | 0.050 |
Why?
|
| Human Growth Hormone | 1 | 2005 | 632 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 11078 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2010 | 2350 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2006 | 1031 | 0.040 |
Why?
|
| Pelvis | 1 | 2004 | 730 | 0.040 |
Why?
|
| Tantalum | 1 | 1990 | 54 | 0.040 |
Why?
|
| Pregnancy | 8 | 2012 | 29297 | 0.040 |
Why?
|
| Spina Bifida Occulta | 1 | 1999 | 31 | 0.040 |
Why?
|
| Postoperative Complications | 3 | 2014 | 15356 | 0.040 |
Why?
|
| Hemostasis, Surgical | 1 | 1990 | 127 | 0.040 |
Why?
|
| Scalp | 1 | 2002 | 383 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2007 | 6334 | 0.040 |
Why?
|
| Fetus | 1 | 2006 | 1882 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 1993 | 933 | 0.040 |
Why?
|
| Orthopedic Fixation Devices | 1 | 1998 | 76 | 0.040 |
Why?
|
| Recurrence | 2 | 2008 | 8384 | 0.040 |
Why?
|
| Pseudarthrosis | 1 | 1998 | 57 | 0.040 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 1998 | 49 | 0.040 |
Why?
|
| Abdomen | 1 | 2004 | 1104 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2017 | 3978 | 0.040 |
Why?
|
| Child Development | 1 | 2010 | 2251 | 0.040 |
Why?
|
| Spine | 2 | 2022 | 1098 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2008 | 1955 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 2165 | 0.040 |
Why?
|
| Intelligence Tests | 1 | 1999 | 497 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 341 | 0.040 |
Why?
|
| Pituitary Diseases | 1 | 1999 | 135 | 0.040 |
Why?
|
| Hypothalamic Diseases | 1 | 1999 | 134 | 0.040 |
Why?
|
| Brain Edema | 1 | 2002 | 596 | 0.040 |
Why?
|
| Neoplasm Seeding | 1 | 2018 | 86 | 0.040 |
Why?
|
| Skull | 1 | 2002 | 808 | 0.040 |
Why?
|
| Purines | 1 | 2021 | 590 | 0.040 |
Why?
|
| Amyloid | 1 | 2022 | 810 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2002 | 1118 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 10750 | 0.040 |
Why?
|
| Tablets | 1 | 2017 | 146 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 766 | 0.040 |
Why?
|
| Linear Energy Transfer | 1 | 2018 | 157 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 1999 | 1770 | 0.040 |
Why?
|
| Spinal Cord | 2 | 2022 | 1774 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 560 | 0.040 |
Why?
|
| Texas | 1 | 2018 | 394 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 556 | 0.040 |
Why?
|
| Pia Mater | 1 | 1997 | 87 | 0.040 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 1998 | 187 | 0.040 |
Why?
|
| Florida | 1 | 2018 | 412 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 3699 | 0.040 |
Why?
|
| Statistics as Topic | 2 | 2015 | 2342 | 0.040 |
Why?
|
| Choline | 3 | 2004 | 502 | 0.030 |
Why?
|
| Tissue Distribution | 2 | 2011 | 2300 | 0.030 |
Why?
|
| Relative Biological Effectiveness | 1 | 2018 | 321 | 0.030 |
Why?
|
| Retreatment | 1 | 1998 | 600 | 0.030 |
Why?
|
| Cerebral Angiography | 2 | 1997 | 1241 | 0.030 |
Why?
|
| Equipment Failure | 1 | 1998 | 570 | 0.030 |
Why?
|
| Syndrome | 2 | 2005 | 3249 | 0.030 |
Why?
|
| World Health Organization | 1 | 2022 | 1298 | 0.030 |
Why?
|
| Physicians | 1 | 2014 | 4536 | 0.030 |
Why?
|
| Prolactinoma | 1 | 1996 | 110 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 1999 | 635 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 2846 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2016 | 396 | 0.030 |
Why?
|
| Pneumothorax | 1 | 1998 | 373 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 417 | 0.030 |
Why?
|
| Research Design | 1 | 2011 | 6061 | 0.030 |
Why?
|
| Mental Disorders | 1 | 1995 | 6639 | 0.030 |
Why?
|
| Intestinal Obstruction | 1 | 1998 | 431 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 1998 | 984 | 0.030 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1999 | 686 | 0.030 |
Why?
|
| Brain Chemistry | 3 | 2004 | 969 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2021 | 949 | 0.030 |
Why?
|
| Phenylalanine | 1 | 1996 | 361 | 0.030 |
Why?
|
| Cloaca | 1 | 1994 | 52 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2007 | 2960 | 0.030 |
Why?
|
| Empyema, Subdural | 1 | 1994 | 12 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 397 | 0.030 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1995 | 109 | 0.030 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 1998 | 386 | 0.030 |
Why?
|
| Moyamoya Disease | 1 | 1997 | 238 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 1999 | 3478 | 0.030 |
Why?
|
| Spinal Neoplasms | 1 | 2000 | 712 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2004 | 2714 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 591 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2019 | 5096 | 0.030 |
Why?
|
| Meningoencephalitis | 1 | 1994 | 82 | 0.030 |
Why?
|
| Carotid Artery Diseases | 1 | 1990 | 862 | 0.030 |
Why?
|
| Age of Onset | 1 | 2020 | 3249 | 0.030 |
Why?
|
| Child Abuse | 1 | 2002 | 1052 | 0.030 |
Why?
|
| Dandy-Walker Syndrome | 1 | 1993 | 43 | 0.030 |
Why?
|
| Uncertainty | 1 | 2018 | 741 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 2016 | 580 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1999 | 2519 | 0.030 |
Why?
|
| Pedigree | 1 | 2000 | 4557 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 4883 | 0.030 |
Why?
|
| Orbit | 1 | 1996 | 439 | 0.030 |
Why?
|
| Medical Records | 1 | 1998 | 1391 | 0.030 |
Why?
|
| Neuroglia | 1 | 1998 | 937 | 0.030 |
Why?
|
| Arachnoid Cysts | 1 | 1993 | 60 | 0.030 |
Why?
|
| Optic Nerve Diseases | 1 | 1996 | 335 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 1995 | 917 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 799 | 0.020 |
Why?
|
| Time Factors | 3 | 2020 | 39622 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2007 | 3328 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2006 | 3462 | 0.020 |
Why?
|
| Suppositories | 1 | 1980 | 15 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 1376 | 0.020 |
Why?
|
| Inpatients | 1 | 2023 | 2515 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2023 | 2269 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 3647 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 6517 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2011 | 204 | 0.020 |
Why?
|
| Consensus | 1 | 2020 | 3017 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1712 | 0.020 |
Why?
|
| Encephalitis | 1 | 1994 | 428 | 0.020 |
Why?
|
| Intracranial Aneurysm | 1 | 1990 | 1206 | 0.020 |
Why?
|
| Proteinuria | 1 | 2013 | 638 | 0.020 |
Why?
|
| Bone Diseases | 1 | 2004 | 413 | 0.020 |
Why?
|
| Disease Management | 1 | 2021 | 2456 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 6463 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 1993 | 3072 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2011 | 342 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 1996 | 1405 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 635 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2010 | 516 | 0.020 |
Why?
|
| Carcinogens | 1 | 1980 | 448 | 0.020 |
Why?
|
| Critical Care | 1 | 2021 | 2664 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2016 | 2589 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2021 | 3314 | 0.020 |
Why?
|
| Clostridium Infections | 1 | 1995 | 554 | 0.020 |
Why?
|
| Age Factors | 2 | 2021 | 18157 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 2010 | 489 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2023 | 4593 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2004 | 1485 | 0.020 |
Why?
|
| Aged | 6 | 2005 | 164383 | 0.020 |
Why?
|
| Pneumonia | 1 | 1998 | 2116 | 0.020 |
Why?
|
| Logistic Models | 3 | 2011 | 13170 | 0.020 |
Why?
|
| Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2006 | 19 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 1086 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 1520 | 0.020 |
Why?
|
| Hallucinations | 1 | 2009 | 358 | 0.020 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2006 | 38 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2010 | 1367 | 0.020 |
Why?
|
| Prevalence | 2 | 2011 | 15312 | 0.020 |
Why?
|
| Cell Movement | 1 | 1998 | 5166 | 0.020 |
Why?
|
| Cerebellum | 1 | 1993 | 1486 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 9107 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2006 | 302 | 0.020 |
Why?
|
| Massachusetts | 1 | 2018 | 8609 | 0.020 |
Why?
|
| Hyperkinesis | 1 | 2005 | 88 | 0.020 |
Why?
|
| Arthralgia | 1 | 2009 | 452 | 0.020 |
Why?
|
| Nystagmus, Pathologic | 1 | 2005 | 104 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2023 | 40534 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2009 | 1417 | 0.010 |
Why?
|
| Case-Control Studies | 3 | 1999 | 21693 | 0.010 |
Why?
|
| Thioguanine | 1 | 2003 | 44 | 0.010 |
Why?
|
| Procarbazine | 1 | 2003 | 174 | 0.010 |
Why?
|
| Lomustine | 1 | 2003 | 60 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2008 | 1616 | 0.010 |
Why?
|
| Hospitalization | 2 | 2021 | 10333 | 0.010 |
Why?
|
| Neutrophils | 1 | 2016 | 3709 | 0.010 |
Why?
|
| Hydrogen | 1 | 2003 | 173 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 2229 | 0.010 |
Why?
|
| Middle Aged | 8 | 2005 | 214618 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 1996 | 3744 | 0.010 |
Why?
|
| Pandemics | 1 | 2023 | 8443 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1993 | 515 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 25184 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2003 | 640 | 0.010 |
Why?
|
| Vomiting | 1 | 2005 | 629 | 0.010 |
Why?
|
| Acoustic Impedance Tests | 1 | 1982 | 108 | 0.010 |
Why?
|
| Eye | 1 | 2006 | 705 | 0.010 |
Why?
|
| Protons | 1 | 2007 | 1116 | 0.010 |
Why?
|
| Benzamides | 1 | 2007 | 1347 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 2793 | 0.010 |
Why?
|
| Incidence | 1 | 2019 | 20820 | 0.010 |
Why?
|
| Vincristine | 1 | 2003 | 1032 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 3695 | 0.010 |
Why?
|
| Photomicrography | 1 | 2000 | 71 | 0.010 |
Why?
|
| Gamma Cameras | 1 | 2000 | 34 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7280 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2006 | 2616 | 0.010 |
Why?
|
| Carboplatin | 1 | 2003 | 802 | 0.010 |
Why?
|
| Stainless Steel | 1 | 1990 | 79 | 0.010 |
Why?
|
| Movement | 1 | 2006 | 1466 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2003 | 493 | 0.010 |
Why?
|
| Twins, Monozygotic | 1 | 2001 | 463 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2009 | 1874 | 0.010 |
Why?
|
| Syringomyelia | 1 | 1999 | 67 | 0.010 |
Why?
|
| Boston | 1 | 2011 | 9213 | 0.010 |
Why?
|
| Bone Diseases, Developmental | 1 | 1999 | 128 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 1255 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 1999 | 291 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2004 | 3583 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2005 | 1905 | 0.010 |
Why?
|
| Nerve Compression Syndromes | 1 | 1999 | 161 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2005 | 1792 | 0.010 |
Why?
|
| Celiac Disease | 1 | 2005 | 806 | 0.010 |
Why?
|
| Spinal Dysraphism | 1 | 1999 | 167 | 0.010 |
Why?
|
| Spinal Cord Compression | 1 | 1999 | 229 | 0.010 |
Why?
|
| Magnetics | 1 | 1990 | 599 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 2000 | 748 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2010 | 5901 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1981 | 4095 | 0.010 |
Why?
|
| Electroencephalography | 2 | 1998 | 6069 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 1995 | 57586 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 1636 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 8294 | 0.010 |
Why?
|
| Cholesterol | 1 | 2003 | 2880 | 0.010 |
Why?
|
| Oxygen | 1 | 2006 | 4182 | 0.010 |
Why?
|
| Models, Structural | 1 | 1993 | 343 | 0.010 |
Why?
|
| Gadolinium | 1 | 1998 | 945 | 0.010 |
Why?
|
| Hypertension | 1 | 2013 | 8366 | 0.010 |
Why?
|
| Metronidazole | 1 | 1995 | 228 | 0.010 |
Why?
|
| Genotype | 1 | 2008 | 12788 | 0.010 |
Why?
|
| AIDS Dementia Complex | 1 | 1994 | 154 | 0.010 |
Why?
|
| Liver | 1 | 2009 | 7382 | 0.010 |
Why?
|
| Cisterna Magna | 1 | 1993 | 40 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2006 | 4399 | 0.010 |
Why?
|
| Melanoma | 1 | 1981 | 5574 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1997 | 1811 | 0.010 |
Why?
|
| Penicillins | 1 | 1995 | 393 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1981 | 5685 | 0.010 |
Why?
|
| Life Expectancy | 1 | 1998 | 1223 | 0.010 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1994 | 663 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 23464 | 0.010 |
Why?
|
| Nevus, Pigmented | 1 | 1981 | 214 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 9455 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 16261 | 0.000 |
Why?
|
| Congenital Abnormalities | 1 | 1993 | 698 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 15555 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1996 | 5997 | 0.000 |
Why?
|
| Immunity, Cellular | 1 | 1981 | 1550 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 17869 | 0.000 |
Why?
|
| Risk Factors | 1 | 2011 | 72447 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1998 | 12227 | 0.000 |
Why?
|
| Compliance | 1 | 1982 | 100 | 0.000 |
Why?
|
| Air Pressure | 1 | 1982 | 74 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1981 | 4823 | 0.000 |
Why?
|
| Ear Diseases | 1 | 1982 | 172 | 0.000 |
Why?
|
| Otitis Media | 1 | 1982 | 283 | 0.000 |
Why?
|
| Mice | 1 | 2004 | 80251 | 0.000 |
Why?
|
| Animals | 2 | 2004 | 166558 | 0.000 |
Why?
|
| Rats | 1 | 1980 | 23696 | 0.000 |
Why?
|